Antenatal Multiple Micronutrient Supplementation (MMS) in Indonesia
NCT ID: NCT06225791
Last Updated: 2025-06-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
5384 participants
INTERVENTIONAL
2023-12-25
2025-03-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Examine different MMS delivery strategies (i.e., packaging strategies and behavior change communication (BCC) strategies) in relation to MMS adherence.
* Assess acceptability, feasibility, fidelity, and coverage of MMS program implementation within antenatal care services (ANC)
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Implementation of Multiple Micronutrient Supplementation (MMS) for Pregnant Women in Uganda
NCT06835738
Increasing Access to Multiple Micronutrient Supplementation - A Pilot Intervention at up to 15 Clinics in Botswana
NCT05703373
NutFish and Nutrient Supplementation in Pregnancy Class to Improve Maternal and Birth Outcomes
NCT02959125
Antenatal Micronutrient Supplementation and Infant Survival
NCT00860470
Antenatal Micronutrient Supplementation and Birth Weight
NCT00115271
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Test different MMS delivery strategies (bottle count \[90 vs. 180 tablets\] and communication strategies \[BCC vs. expanded BCC vs. MMS orientation only\]) for enhancing supplementation consumption - measured as coverage and adherence.
* Assess acceptability, feasibility, and fidelity of MMS program implementation within antenatal care services (ANC)
More specifically, the investigators will implement and evaluate different MMS packaging (90 count bottle vs 180-count bottle) strategies and behavior change communication (BCC) strategies. The 3 BCC approaches are further described below.
* BCC, BCC without Interpersonal Communication (IPC) strategy is a briefer more basic approach that hopes to improve health care providers knowledge about MMS and the providers ability to communicate with pregnant women. This approach will be rolled out by training one district-level facilitator in each district to become a trainer who will be responsible for training health providers in the corresponding study sub-districts.
* Expanded BCC ('BCC with Interpersonal Communication \[IPC\]') needs more intensive training of master trainers to train health care providers and focuses more on the counselling skills portion. The BCC without IPC is more feasible to implement within the existing system, the investigators anticipate that the BCC with IPC achieve better behavior change results.
* MMS Orientation: Women in the control group will receive the existing standard of counselling care. The providers will not be given any sort of training on counselling. Due to the fact that MMS is a new product that the providers will be providing pregnant women, all health care providers will receive a standard MMS orientation so providers are comfortable with the new supplement.
The study will be conducted in 25 districts representing the western, central, and eastern regions of Indonesia, Indonesia's socio-cultural diversity, and varying capacity of ANC systems across districts. After selection, the 25 districts were divided to receive high-intensity (8 districts), moderate-intensity (5 districts), or low-intensity (12 districts) evaluation activities with those exposed to high-intensity evaluation efforts having comprehensive individual-level data collected by study employed data collectors while the low-and moderate-intensity district data collection efforts are being done within the context of the existing health system.
1. High intensity evaluation areas (8 districts) Evaluation of MMS acceptability, coverage, adherence, feasibility, and fidelity will include data collection from health professionals and pregnant women by study data collectors, and by ANC monitoring activities.
2. Moderate intensity evaluation areas (5 districts) Evaluation of ANC records with aggregate coverage and adherence numbers will be shared with investigators. In addition, data collectors will collect MMS acceptability, feasibility, and fidelity data within 2 of those 5 districts.
3. Low intensity evaluation area (12 districts) Evaluation of ANC records with aggregate coverage and adherence numbers will be shared with investigators. In addition, a household coverage survey will be administered in a subset of districts (n=6) post-intervention to examine MMS acceptability, adherence, coverage, and implementation feasibility and fidelity. The coverage survey will be designed after 6 months of implementation and will be submitted as a separate application to the Johns Hopkins Bloomberg School of Public Health Institutional Review Board, and a separate entry into Clinicaltrials.gov.
Within the 8 high-intensity districts and 5 moderate-intensity districts that are the subject of this Clinicaltrials.gov submission, the study will utilize a three-arm cluster randomized design (with sub-district health center as the unit of randomization).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
* Arm/sub-district 1: Provision of 90-count bottles x 2, with standard MMS delivery strategies and MMS orientation
* Arm/sub-district 2: Provision of 90-count bottles x 2, with enhanced MMS deliveries strategy (3 with MMS orientation with BCC; 5 with MMS orientation with expanded BCC)
* Arm/sub-district 3: Provision of 180-count bottles x 1, with enhanced MMS delivery strategy (3 with MMS orientation with BCC; 5 with MMS orientation with expanded BCC)
HEALTH_SERVICES_RESEARCH
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard MMS delivery with two 90-count bottles
Pregnant women are provided with two 90-count bottles of MMS at two different time points during pregnancy, along with standard MMS delivery strategy (MMS orientation only). (1 sub-district within each of the 13 districts with high- or moderate-intensity evaluation).
No interventions assigned to this group
Enhanced MMS delivery with two 90-count bottles
Pregnant women are provided with two 90-count bottles of MMS at two different time points during pregnancy, along with enhanced MMS delivery strategy (5 districts with MMS orientation with BCC; 8 districts with MMS orientation with expanded BCC). (1 sub-district within each of the 13 districts with high- or moderate-intensity evaluation).
MMS (90x2) + BCC or expanded BCC
Provision of 90-count bottles x 2, with enhanced MMS delivery strategy (5 districts with MMS orientation with BCC; 8 districts with MMS orientation with expanded BCC)
Enhanced MMS delivery with one 180-count bottle
Pregnant women are provided with one 180-count bottle of MMS along with enhanced MMS delivery strategy (5 districts with MMS orientation with BCC; 8 with MMS orientation with expanded BCC). (1 sub-district with each of the 13 districts with high- or moderate-intensity evaluation).
MMS (180x1) + BCC or expanded BCC
Provision of 180-count bottles x 1, with enhanced MMS delivery strategy (5 districts with MMS orientation with BCC; 8 districts with MMS orientation with expanded BCC)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MMS (90x2) + BCC or expanded BCC
Provision of 90-count bottles x 2, with enhanced MMS delivery strategy (5 districts with MMS orientation with BCC; 8 districts with MMS orientation with expanded BCC)
MMS (180x1) + BCC or expanded BCC
Provision of 180-count bottles x 1, with enhanced MMS delivery strategy (5 districts with MMS orientation with BCC; 8 districts with MMS orientation with expanded BCC)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Received MMS at ANC 1
* Gestational age at ANC 1 ≤ 20 weeks (verified by health professionals)
* Consent provided to participate in the study.
* Enrolled in ANC 1 through government health facilities.
* Received MMS at ANC 1
* Gestational age at ANC 1 ≤ 20 weeks (verified by health professionals)
* Consent provided to participate in qualitative component of study.
* Received MMS for at least 3 months.
* Attended \> 2 ANC visits.
* \< 4 weeks post-partum
* Government health workers who provide ANC services (e.g., midwives, general practitioners, and nutritionists)
* Government health facility management staff (e.g., Head of Puskesmas Community Health Clinic, Coordinating Midwife, Head of Pharmacy)
* Willing to give consent to participate in the FGD.
* District-, provincial-, or national-level decision-makers working in nutrition, maternal, newborn and child health, or pharmaceutical roles associated with the antenatal care system in Indonesia.
* Willing to give consent to participate in the FGD or IDI.
Exclusion Criteria
* PW planning to move outside study district during study period.
* Enrolled in Sample 1
* Women who are more than 4 weeks postpartum.
• None
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Indonesia University
OTHER
Hasanuddin University
OTHER
Universitas Airlangga
OTHER
Vitamin Angels
UNKNOWN
Johns Hopkins Bloomberg School of Public Health
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Endang Achadi, PhD
Role: PRINCIPAL_INVESTIGATOR
Indonesia University
Kristin Hurley, PhD, MPH
Role: PRINCIPAL_INVESTIGATOR
Johns Hopkins Bloomberg School of Public Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Universitas Indonesia
Jakarta, , Indonesia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB00016428 / MOD00004017
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.